Dr. Reddy's Laboratories Ltd ADR RDY

$13.21 -0.02 (-0.15%)

Valuation

Market cap: 11,042,698,000
Revenue TTM: $3,580,000,000
Net income TTM: $456,000,000
PE ratio: 28.06
Forward PE: 29.48
Profit margin: 12.74%
Debt to equity: 0.19

Trading

Volume: 3,909,200
Avg volume: 2,924,304
Day's range: $13.18 – $13.57
Shares out: 834,671,000
Stochastic %K: 61%
Beta: 0.29
Analysts: Hold
Price target: $14.17

Price

Company profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 91 40 4900 2900
Website: https://www.drreddys.com
Address: 8-2-337, Road No. 3, Banjara Hills, Hyderabad, India

Latest news

No headlines yet.

Stocktwits

filecrux Oct 23, 6:15 PM

$RDY Dr. Reddy's September-quarter profit fell 36% to ₹925 Cr on lower lenalidomide sales, price erosion, higher SG&A and lower other income. 🏢 Dr. Reddy's Laboratories is a Hyderabad-based generic drug maker whose NYSE shares traded at $13.335 at 14:10 ET on October 23, 2026 📉 Profit attributable to shareholders for the September 2026 quarter fell 36% from a year earlier to ₹925 Cr, while revenue slipped just 1.5% to ₹8,671 Cr 📉 EBITDA margin fell to 20.6% from 26.7% and diluted EPS to ₹11.1 from ₹17.3, as price erosion and product mix cut gross margin while SG&A rose 6% and other income fell 66% 📈 Against that, profit roughly doubled from the June quarter, when EBITDA margin was 12.5% after a ₹240 Cr semaglutide provision, and India grew 17% and Emerging Markets 24% 📅 Next: Dengue vaccine QDENGA is set to launch in India's private markets in the first half of 2027; watch the replies to the FDA Form 483s Source: SEC 6-Ks, Oct 23 (results deck + interim report)

0 replies

EarningsInsider Oct 23, 4:38 PM

https://www.marketbeat.com/earnings/reports/2026-10-23-dr-reddys-laboratories-limited-stock/ $RDY Dr. Reddy's Laboratories Earnings Transc

0 replies

zampy Oct 23, 3:51 PM

$COYA $RDY NOW $13.30 UP 1.8B LAST 6 WEEKS...We lost 1 point $5 to $4...25m mkt off.... Interesting isnt it???

0 replies

Jwa68 Oct 21, 1:43 PM

$COYA $RDY https://www.prnewswire.com/news-releases/answer-als-announces-nfl-commitment-of-500-000-to-champion-insights-to-investigate-why-athletes-veterans-and-first-responders-face-higher-als-risk-302914589.html

0 replies

Jwa68 Oct 20, 1:13 AM

$COYA I block most posters here and other places that I find ineducated and ignorant. Seeing a few here as of late that don't merit engagement. Most of reasonable intelligence would argue that the true value of Coya is that when ALS data is good, it will unlock the value of FTD, AD and so many by other indications. The science goes from validated to a literal no brainer for other bigger indications. Still looking for a deal likely by year end....$XBI $RDY DYDD

2 replies

shnitzerbittle Oct 17, 5:01 PM

$TNXP They might be profitable in 2028 at the current trajectory, not because of lack of sales but because they burn so much money. In fact so much ($440,000 losses) a day that they will burn thru their cash pile in just over a year. This means dilution is not a fear it is a reality. On top of that there is a very high chance that Dr. Reddy can defeat the patent protection by 2028. So just about the time they become profitable the odds are high they will lose 80- 90 percent of their sales to a generic. It's brutal because after spending all that money and time to develop Tonmya the financial benefit is more likely to go to $RDY than it is to go to $TNXP.

2 replies

Jwa68 Oct 14, 12:41 PM

$COYA The drug clearly is working. Any other market...we'd be $10 already. $XBI $RDY $BMY

0 replies

Jwa68 Oct 8, 8:03 PM

$COYA $RDY $BMY https://podcasts.apple.com/us/podcast/rarecast/id954082143?i=1000793819739

1 replies